WebOct 30, 2024 · Introduction In the event-driven GRIPHON randomised-controlled trial, the oral prostacyclin receptor agonist selexipag significantly reduced the risk of disease progression (composite primary endpoint of morbidity/mortality), compared with placebo, in patients with pulmonary arterial hypertension (PAH). The ongoing open-label extension …

Selexipag in the management of pulmonary arterial hypertension: …

WebThe information below is from a post hoc subgroup analysis of the GRIPHON trial. View the GRIPHON pivotal data for context of the overall population. Patients receiving an ERA … WebThese findings, however, cannot be extrapolated to dual background therapy (as in the GRIPHON trial). The 26% reduction in the rate of clinical worsening with oral TRE is less than the 40% reduction for selexipag in the GRIPHON trial, but becomes similar (39%) when adjusted for the greater occurrence of baseline risk factors in the TRE versus ... swan creek recreation centre

GRIPHON Study on Selexipag – All About Cardiovascular System …

WebThese findings, however, cannot be extrapolated to dual background therapy (as in the GRIPHON trial). The 26% reduction in the rate of clinical worsening with oral TRE is less … WebThe New England Journal of Medicine WebThe pivotal GRIPHON study is extensively presented. Expert opinion: Selexipag is the first IP receptor to reduce the morbidity/mortality composite endpoint of the GRIPHON study, a large, randomized, placebo-controlled study. The TRITON study failed to demonstrate a clear benefit of initial triple oral therapy including selexipag compared to ... swan creek recreation area mo